ACXP Acurx Pharmaceuticals, Inc. Stock Quote

ACXP [NASD]

Index	-	P/E	-	EPS (ttm)	-1.55	Insider Own	20.60%	Shs Outstand	10.23M	Perf Week	-13.57%
Market Cap	24.93M	Forward P/E	-	EPS next Y	-1.32	Insider Trans	0.00%	Shs Float	7.87M	Perf Month	-39.50%
Income	-13.90M	PEG	-	EPS next Q	-0.35	Inst Own	3.10%	Short Float	0.45%	Perf Quarter	-33.15%
Sales	-	P/S	-	EPS this Y	-209.80%	Inst Trans	287.97%	Short Ratio	2.00	Perf Half Y	-47.96%
Book/sh	1.04	P/B	2.33	EPS next Y	0.80%	ROA	-97.80%	Target Price	12.00	Perf Year	-
Cash/sh	1.08	P/C	2.25	EPS next 5Y	-	ROE	-105.40%	52W Range	2.33 - 8.74	Perf YTD	-44.00%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-71.40%	Beta	-
Dividend %	-	Quick Ratio	17.90	Sales past 5Y	-	Gross Margin	-	52W Low	7.30%	ATR	0.27
Employees	3	Current Ratio	17.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	30.86	Volatility	8.55% 8.39%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-68.90%	Profit Margin	-	Rel Volume	0.23	Prev Close	2.42
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 11 BMO	Payout	-	Avg Volume	17.62K	Price	2.50
Recom	2.00	SMA20	-21.67%	SMA50	-27.87%	SMA200	-41.49%	Volume	3,936	Change	3.31%

May-11-22 07:01AM	Acurx Pharmaceuticals, Inc. Reports First Quarter 2022 Results and Provides Business Update PR Newswire
Apr-29-22 08:01AM	Acurx Pharmaceuticals, Inc. to Discuss 2022 First Quarter Financial Results on May 11, 2022 Conference Call and Provide Business Update PR Newswire
Mar-24-22 03:23PM	Acurx Pharmaceuticals (NASDAQ:ACXP) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Mar-17-22 07:01AM	Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update PR Newswire
Mar-16-22 08:01AM	Acurx Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28-30, 2022 from 9:00 a.m. - 5:00 p.m. EDT PR Newswire
Mar-07-22 08:01AM	Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update PR Newswire +8.68%
Feb-07-22 08:01AM	Acurx Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious Diseases PR Newswire
Dec-06-21 08:01AM	Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI) PR Newswire +5.30%
Nov-12-21 06:01PM	Acurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business Update PR Newswire
Nov-08-21 08:01AM	Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference PR Newswire +5.62%
Nov-01-21 08:01AM	Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference PR Newswire +9.40%
Oct-27-21 08:01AM	Acurx Pharmaceuticals to Discuss 2021 Third Quarter Financial Results on November 15, 2021 Conference Call and Provide Business Update PR Newswire
Oct-04-21 09:00AM	Acurx Presents Positive Ibezapolstat Microbiome Data from Its Phase 2a Trial at IDWeek PR Newswire -10.56%
Sep-30-21 08:00AM	Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021 PR Newswire
Sep-29-21 08:00AM	Acurx Pharmaceuticals to Participate in the A.G.P. Biotech and Specialty Pharma Conference October 13, 2021 PR Newswire +9.21%
Sep-27-21 08:00AM	Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI in a Scientific Poster Presentation at IDWeek 2021 Conference PR Newswire
Sep-25-21 08:02AM	We Think Acurx Pharmaceuticals (NASDAQ:ACXP) Can Easily Afford To Drive Business Growth Simply Wall St.
Sep-13-21 08:03AM	CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts Newsfile +11.00%
Sep-02-21 08:00AM	Acurx Pharmaceuticals to Join the Russell Microcap Index® PR Newswire
Aug-31-21 08:00AM	Acurx Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 PR Newswire +5.08%
Aug-17-21 07:00AM	CEO Presenting on the Emerging Growth Conference on August 18. Register Now GlobeNewswire -10.87%
Aug-16-21 04:05PM	Acurx Pharmaceuticals, Inc. Reports Second Quarter 2021 Results and Provides Business Update PR Newswire -11.88%
Aug-12-21 08:00AM	Acurx Pharmaceuticals to Present at the Emerging Growth Conference on August 18, 2021 PR Newswire
Aug-05-21 08:00AM	Acurx Pharmaceuticals Joins the Antimicrobials Working Group PR Newswire
Aug-02-21 08:00AM	Health Holland Awards Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals PR Newswire
Jul-28-21 08:00AM	Acurx Pharmaceuticals to Discuss 2021 Second Quarter Financial Results on August 17, 2021 Conference Call and Provide Business Update PR Newswire
Jul-07-21 09:00AM	Acurx Announces Filing of Provisional Patent Application for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving the Health of the Gut Microbiome PR Newswire +5.05%
Jul-01-21 08:00AM	Acurx Announces New Ibezapolstat Data on Anti-Recurrence Mechanisms in CDI at Prominent International Conference PR Newswire
Jun-29-21 04:01PM	ACURX PHARMACEUTICALS, Inc. Announces Closing of INITIAL Public Offering OF common stock AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES PR Newswire
Jun-25-21 01:23PM	7 Companies Go Public Today. What Investors Need to Know. Barrons.com
08:00AM	Acurx Pharmaceuticals, Inc. announces pricing of $15 Million underwritten Initial public offering of common stock PR Newswire

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sailer Carl	Director	Nov 23	Buy	4.84	5,161	24,979	73,078	Nov 24 04:06 PM
LUCI DAVID P	President and CEO	Nov 19	Buy	4.80	5,200	24,960	1,008,723	Nov 22 04:05 PM
DELUCCIA ROBERT J	Director	Nov 19	Buy	4.90	5,034	24,672	1,031,461	Nov 22 04:05 PM
Sailer Carl	Director	Jun 29	Buy	6.00	12,500	75,000	67,917	Sep 10 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience